Oxabel
(Oxaliplatin)
Composition:
Each vial contains oxaliplatin (50 mg or 100 mg)
ATC Code
L01XA03 — Oxaliplatin
Structure
Description
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility.
Indication
- Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Associated Conditions
- Advanced Colorectal Cancer
- Advanced Ovarian Cancer
- Advanced Pancreatic Cancer
- Chronic Lymphocytic Leukemia (CLL) – Refractory
- Colon Cancer Stage III
- Esophageal Cancers
- Malignant Neoplasm of Stomach
- Advanced biliary adenocarcinoma
- Refractory Neuroendocrine Tumour
- Refractory Non-Hodgkin’s lymphoma
- Refractory Testicular cancer
Pharmacodynamics
Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
Mechanism of Action
Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific.